InsidersTradesSigma
Track the Cingulate Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Cingulate Inc. has logged 42 reports. The latest transaction was disclosed on 8 June 2026 (Acquisition). Among the most active insiders: Callahan Jennifer L.. All data is openly available.
42
Insider Decl.
n/a
Thresholds
€2m
34 ops.
Buy Volume
€21,837
2 ops.
Sell Volume
54Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 June 2026
Declarations42 total
97,276 shares@ US$5.04100.0% of flowCommon StockSEC:0001493152-26-027794:0
Canonical exit: 14 May 2026 (T+90)
4,526 shares0Common StockSEC:0001493152-26-009723:0
6,862 shares0Common StockSEC:0001493152-26-009722:0
5,475 shares0Common StockSEC:0001493152-26-009721:0
15,329 shares0Common StockSEC:0001493152-26-009720:0
4,526 shares0Common StockSEC:0001493152-26-009719:0
19,455 shares@ US$5.047.1% of flowCommon StockSEC:0001493152-26-006027:0
Canonical exit: 7 May 2026 (T+90)
4,864 shares@ US$5.0432.9% of flowCommon StockSEC:0001493152-26-006026:0
Canonical exit: 7 May 2026 (T+90)
6,809 shares@ US$5.0472.2% of flowCommon StockSEC:0001493152-26-006025:0
Canonical exit: 7 May 2026 (T+90)
1,946 shares@ US$5.04100.0% of flowCommon StockSEC:0001493152-26-006024:0
Canonical exit: 7 May 2026 (T+90)
202 shares@ US$4.16521.1% of flowCommon StockSEC:0001493152-24-033196:0
341,912 shares@ US$0.0020.1% of flowCommon StockSEC:0001493152-24-014504:0
55 shares@ US$27.103.2% of flowCommon StockSEC:0001493152-24-011034:0
Canonical exit: 13 Jun 2022 (T+90)
5,000 shares@ US$0.66977.7% of flowCommon StockSEC:0001493152-23-032961:0
Canonical exit: 14 Dec 2023 (T+90)
1,823,155 shares@ US$0.548583.1% of flowCommon StockSEC:0001493152-23-028563:0
Canonical exit: 9 Nov 2023 (T+90)
4,000 shares@ US$1.089.3% of flowCommon StockSEC:0001493152-23-017842:0
Canonical exit: 10 Aug 2023 (T+90)
10,000 shares@ US$1.016685.2% of flowCommon StockSEC:0001493152-22-035892:0
Canonical exit: 16 Mar 2023 (T+90)
7,548 shares@ US$0.989416.6% of flowCommon StockSEC:0001493152-22-035631:0
Canonical exit: 14 Mar 2023 (T+90)
1,733 shares@ US$1.0114.8% of flowCommon StockSEC:0001493152-22-035633:0
Canonical exit: 13 Mar 2023 (T+90)
28,934 shares@ US$0.98232.5% of flowCommon StockSEC:0001493152-22-035632:0
Canonical exit: 13 Mar 2023 (T+90)
1,111 shares@ US$0.899826.6% of flowCommon StockSEC:0001493152-22-034191:0
Canonical exit: 21 Feb 2023 (T+90)
3,487 shares@ US$0.97987.8% of flowCommon StockSEC:0001493152-22-034042:0
Canonical exit: 26 Feb 2023 (T+90)
3,575 shares@ US$0.8427.9% of flowCommon StockSEC:0001493152-22-033848:0
Canonical exit: 21 Feb 2023 (T+90)
85,000 shares@ US$0.880687.1% of flowCommon StockSEC:0001493152-22-033748:0
Canonical exit: 20 Feb 2023 (T+90)
17,532 shares@ US$1.266748.2% of flowCommon StockSEC:0001493152-22-026717:0
25 of 42 declarations
关于 Cingulate Inc.
Cingulate Inc. 是一家在美国纳斯达克市场上市的临床阶段生物制药公司。对于讲法语的投资者来说，最好将其理解为一家专注于中枢神经系统的小型生物技术公司，而非多元化的制药平台。该公司专注于注意力缺陷/多动障碍 (ADHD) 和焦虑相关疾病，利用其专有的精准定时释放™ (PTR™) 药物递送平台开发品牌化的下一代药物产品，旨在提供全天更一致的覆盖，并减少多剂量方案带来的缺点。（[cingulate.com](https://www.cingulate.com/investors?utm_source=openai)） Cingulate 的根源在于 Cingulate Therapeutics，其运营基地位于美国堪萨斯城。这个地理位置很重要：该公司围绕中西部生物技术足迹而非大型沿海制药中心建立。其战略是围绕 PTR™ 建立少量差异化资产，其商业论点基于改进的给药便利性、更长的作用持续时间以及比简单重新配方更强的知识产权保护。该公司称自己是一家专注于 ADHD 和焦虑相关疾病创新候选产品的三期临床阶段生物制药公司。（[cingulate.com](https://www.cingulate.com/news-releases/news-release-details/cingulate-therapeutics-announces-expansion-accommodate-growth?utm_source=openai)） 主要项目是 CTx-1301 (右旋甲基苯丙胺盐酸盐)，这是 Cingulate 的旗舰 ADHD 候选药物。2025年10月，美国 FDA 接受了该公司的《新药申请》，并设定了 PDUFA 目标行动日期为2026年5月31日，使监管审查成为近期的核心催化剂。2026年3月，该公司表示已收到 CTx-1301 的美国专利授权通知，并获得了额外的欧洲专利授权，这加强了围绕该主要资产的知识产权叙述。Cingulate 还在2025年任命 Bryan Downey 为首席商务官，为潜在的上市做准备，表明管理层正在积极建立商业准备，以应对可能的批准决定。（[cingulate.com](https://www.cingulate.com/news-releases/news-release-details/cingulate-names-industry-veteran-bryan-downey-chief-commercial/?utm_source=openai)） 从竞争角度来看，Cingulate 在一个由更大的 ADHD 特许经营权主导的市场中仍然是一个利基参与者。其机会在于 PTR™ 是否能转化为有意义的临床和商业差异化，特别是对于寻求全天症状覆盖且给药问题较少的患者和处方医生。同时，投资案例仍然是二元的且对执行敏感，因为该公司仍处于商业化前阶段，依赖于监管结果、供应链准备和资本获取。2026年的最新公司更新显示，Cingulate 通过私募融资筹集了12 million美元，并在2026年第一季度结束时拥有更强的现金头寸，有助于为下一个主要里程碑的运营提供资金。因此，对于投资者来说，这个故事是关于高监管杠杆、知识产权驱动的差异化以及在美国纳斯达克市场集中的产品风险。（[nasdaq.com](https://www.nasdaq.com/press-release/cingulate-announces-closing-12-million-private-placement-priced-market-under-nasdaq?utm_source=openai)）
